Schizophrenia: US approves first new treatment in decades
Author:
Abstract
No abstract availableThis publication has 2 references indexed in Scilit:
- Efficacy and Safety of Xanomeline-Trospium Chloride in SchizophreniaJAMA Psychiatry, 2024
- Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trialThe Lancet, 2023